Press releases

2023-07-04 13:00 The subscription period in Lipum’s rights issue begins today and the CEO has participated in a company presentation and CEO interview with Erik Penser Bank
Lipum AB (publ) ("Lipum" or the "Company") announces that the subscription period in the Company’s capital raising begins today...
2023-06-30 08:55 Lipum publishes an information memorandum in connection with the company’s forthcoming rights issue Regulatory
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA...
2023-06-27 13:45 Lipum AB - Report from the Extraordinary General Meeting Regulatory
An Extraordinay General Meeting (the ”EGM”) in Lipum AB (publ), corporate identity number 556813-5999 (”Lipum” or the “Company”)...
2023-06-08 09:14 Lipum has resolved on a rights issue of approximately SEK 26.4 million at a subscription price of SEK 9.20 per share Regulatory MAR
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA...
2023-05-30 09:10 Lipum AB: BioStock Life Science Spring Summit with Lipum
Do not miss Lipum's presentation at the BioStock Life Science Spring Summit, today May 31 at 10.40. The event starts at 10.00 - see the full programme...
2023-04-25 08:00 Lipum AB – interim report for the period January-March 2023 Regulatory
Lipum AB (publ) has published the interim report for period January to March for 2023. Below is a summary, a complete report (only in Swedish) is available...
2023-03-24 08:00 Lipum AB – Year-end report 2022 Regulatory
Lipum AB (publ) has published the interim and the year-end report for 2022. Below is a summary, a complete report (only in Swedish) is available on the...
2023-03-23 16:50 Lipum's ongoing clinical phase 1 study proceeds as planned
Lipum AB (publ) announces that the clinical phase 1 study with the drug candidate SOL-116 is proceeding as planned. After a fourth dose escalation, a safety...
2023-02-07 13:00 Lipum to participate in following upcoming events
Lipum (publ), a clinical stage biopharmaceutical company focused on chronic inflammatory diseases, today announced its participation in the following upcoming...
2022-12-21 08:30 Lipum AB announces the Nomination Committee for the 2023 Annual General Meeting Regulatory
Lipum AB (publ) ("Lipum") announces its Nomination Committee for the Annual General Meeting 2023. In accordance with the decision at the Annual...
PreviousNext

Investor relations